Dishman Carbogen Amcis Limited — Updates, 06-06-2025: Press Release

Dishman Carbogen Amcis’ subsidiary, CARBOGEN AMCIS AG, is co-investing over CHF 25 million with a key Japanese client to expand ADC drug linker manufacturing capacity at its Aarau and Neuland sites in Switzerland. The upgrade involves adding 850-litre reactors and agitated filter dryers, aimed for completion by 2027. This expansion addresses growing global demand for highly potent APIs and advanced therapies, strengthening production capabilities and securing long-term client relationships.